Janux Therapeutics
JANX
155 hedge funds and large institutions have $1.87B invested in Janux Therapeutics in 2024 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 58 increasing their positions, 33 reducing their positions, and 19 closing their positions.
189% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 19
76% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 33
28% more funds holding
Funds holding: 121 → 155 (+34)
18% more capital invested
Capital invested by funds: $1.59B → $1.87B (+$279M)
4.3% more ownership
Funds ownership: 81.95% → 86.26% (+4.3%)
8% less call options, than puts
Call options by funds: $4.12M | Put options by funds: $4.46M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$73.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$69M |
| 3 |
State Street
Boston,
Massachusetts
|
+$47M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$34M |
| 5 |
BlackRock
New York
|
+$30.5M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$116M |
| 2 |
O
OrbiMed
New York
|
-$60.8M |
| 3 |
RI
RTW Investments
New York
|
-$37.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21M |
JANX Hedge Fund Activity: Q2 2024 in Review
155 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2024, worth a combined $1.87B — up 18% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new JANX positions and 19 closed out — a net gain of 36 holders — while 58 added to existing stakes and 33 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $73.5M. The largest seller was BVF Inc, cutting an estimated $116M.
- 155 institutional investors held Janux Therapeutics (JANX) as of Q2 2024, up from 121 in Q1 2024.
- Funds reported $1.87B of Janux Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
- 55 funds opened new Janux Therapeutics positions in Q2 2024 and 19 closed out, a net change of +36 holders.
- The largest Janux Therapeutics buyer in Q2 2024 was Paradigm Biocapital Advisors, an estimated $73.5M added.
- The largest Janux Therapeutics seller in Q2 2024 was BVF Inc, an estimated $116M sold.
Based on aggregated 13F filings for Q2 2024.